183 results on '"Wanders, Rinus"'
Search Results
2. Gender and age make no difference in the re-irradiation of painful bone metastases: A secondary analysis of the NCIC CTG SC.20 randomized trial
3. Is selective nodal irradiation in non-small cell lung cancer still safe when using IMRT? Results of a prospective cohort study
4. A prospective study comparing the predictions of doctors versus models for treatment outcome of lung cancer patients: A step toward individualized care and shared decision making
5. A Phase I Study of Concurrent Individualized, Isotoxic Accelerated Radiotherapy and Cisplatin–Vinorelbine–Cetuximab in Patients With Stage III Non–Small-Cell Lung Cancer
6. Long-term survival of stage T4N0-1 and single station IIIA-N2 NSCLC patients treated with definitive chemo-radiotherapy using individualised isotoxic accelerated radiotherapy (INDAR)
7. Hypoxia imaging with [18F]HX4 PET in NSCLC patients: Defining optimal imaging parameters
8. State of the Art Radiation Therapy for Lung Cancer 2012: A Glimpse of the Future
9. Is high-dose stereotactic body radiotherapy (SBRT) for stage I non-small cell lung cancer (NSCLC) overkill? A systematic review
10. Radical Treatment of Non–Small-Cell Lung Cancer Patients with Synchronous Oligometastases: Long-Term Results of a Prospective Phase II Trial (Nct01282450)
11. Individualised isotoxic accelerated radiotherapy and chemotherapy are associated with improved long-term survival of patients with stage III NSCLC: A prospective population-based study
12. Treatment with curative intent of stage III non-small cell lung cancer patients of 75 years: A prospective population-based study
13. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: An economic evaluation
14. Standard-dose versus higher-dose prophylactic cranial irradiation (PCI) in patients with limited-stage small-cell lung cancer in complete remission after chemotherapy and thoracic radiotherapy (PCI 99-01, EORTC 22003-08004, RTOG 0212, and IFCT 99-01): a randomised clinical trial
15. Follow-up with 18FDG-PET–CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: A prospective study
16. Can we optimize chemo-radiation and surgery in locally advanced stage III non-small cell lung cancer based on evidence from randomized clinical trials? A hypothesis-generating study
17. Identification of residual metabolic-active areas within individual NSCLC tumours using a pre-radiotherapy 18Fluorodeoxyglucose-PET-CT scan
18. High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL
19. Increased 18F-deoxyglucose uptake in the lung during the first weeks of radiotherapy is correlated with subsequent Radiation-Induced Lung Toxicity (RILT): A prospective pilot study
20. Dyspnea evolution after high-dose radiotherapy in patients with non-small cell lung cancer
21. 18FDG-PET based radiation planning of mediastinal lymph nodes in limited disease small cell lung cancer changes radiotherapy fields: A planning study
22. INCLUSION PRACTICE IN LUNG CANCER TRIALS
23. Time Between the First Day of Chemotherapy and the Last Day of Chest Radiation Is the Most Important Predictor of Survival in Limited-Disease Small-Cell Lung Cancer
24. Progression-Free Survival and Overall Survival Beyond 5 Years of NSCLC Patients With Synchronous Oligometastases Treated in a Prospective Phase II Trial (NCT 01282450)
25. The Relevance of the Revised Version of the International Lung Cancer Staging System for Non-Small-Cell Lung Cancer Treated with Radiotherapy
26. The importance of pre-treatment haemoglobin level in inoperablenon-small cell lung carcinoma treated with radical radiotherapy
27. Comparative evaluation of autocontouring in clinical practice: A practical method using the Turing test
28. Comparative evaluation of autocontouring in clinical practice: A practical method using the Turing test
29. The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study
30. Standard of care in high-dose radiotherapy for localized non-small cell lung cancer
31. Standard of care in high-dose radiotherapy for localized non-small cell lung cancer
32. Is selective nodal irradiation in non-small cell lung cancer still safe when using IMRT? Results of a prospective cohort study
33. Hypoxia imaging with [(18)F]HX4 PET in NSCLC patients : Defining optimal imaging parameters.
34. Total Gross Tumor Volume Is an Independent Prognostic Factor in Patients Treated With Selective Nodal Irradiation for Stage I to III Small Cell Lung Cancer
35. Selective nodal irradiation on basis of (18)FDG-PET scans in limited-disease small-cell lung cancer: a prospective study
36. Total Gross Tumor Volume Is an Independent Prognostic Factor in Patients Treated With Selective Nodal Irradiation for Stage I to III Small Cell Lung Cancer
37. Treatment with curative intent of stage III non-small cell lung cancer patients of 75years: A prospective population-based study
38. Cancer Patients Use Hospital-Based Care Until Death: A Further Analysis of the Dutch Bone Metastasis Study
39. Rotterdam Symptom Checklist--Dutch Version
40. Selective Nodal Irradiation on Basis of 18FDG-PET Scans in Limited-Disease Small-Cell Lung Cancer: A Prospective Study
41. Concurrent celecoxib versus placebo in patients with stage II–III non-small cell lung cancer: A randomised phase II trial
42. Radiation Dose Prescription for Non–Small-Cell Lung Cancer According to Normal Tissue Dose Constraints: An In Silico Clinical Trial
43. HI-CHART: A Phase I/II Study on the Feasibility of High-Dose Continuous Hyperfractionated Accelerated Radiotherapy in Patients With Inoperable Non–Small-Cell Lung Cancer
44. PD2-1-3: Changes in plasma levels of cytokines during fractionated radiotherapy of non-small cell lung cancer (NSCLC): the relation with metabolic response and toxicity
45. P3-046: Personalized High-Dose Continuous Hyperfractionated Accelerated Radiotherapy (HI-CHART) of non-small cell lung cancer (NSCLC) based on normal tissue constraints: a prospective clinical trial
46. PD6-1-8: 18-FDG-PET based planning of limited stage small cell lung cancer changes radiotherapy fields: A planning study
47. D1-02: Initial results from an intergroup phase III trial evaluating two different doses of prophylactic cranial irradiation (PCI) in patients with limited small cell cancer (SCLC) in complete remission (PCI99-01, IFCT 99-01, EORTC 22003-08004, RTOG 0212)
48. Increased therapeutic ratio by 18FDG-PET CT planning in patients with clinical CT stage N2-N3M0 non–small-cell lung cancer: A modeling study
49. Erratum to “ The effect of a single fraction compared to multiple fractions on painful bone metastases: a global analysis of the Dutch Bone Metastasis Study” [Radiother. Oncol. 52 (1999) 101–109]
50. Changes in plasma levels of cytokines during fractionated radiotherapy of non-small cell lung cancer (NSCLC): the relation with metabolic response and toxicity.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.